Edgeline Holdings announced today that it expects to close its acquisition of Intertech Bio by the end of this month. The CEO, Leonard Ivins, stated, “This acquisition will bring an experienced team of scientists that have many years in this industry. We believe that the acquisition of Intertech Bio will significantly enhance the value of our company in the short and long term.”
Intertech Bio is a biopharmaceutical company primarily focused on developing products that can treat cancer, infectious diseases and other medical conditions. Cancer is believed to occur as a result of a number of factors, such as genetic predisposition, chemical agents, viruses and irradiation. These factors result in genetic changes affecting the ability of cells to regulate their growth and differentiation normally.
Currently, the most common methods of treating patients include surgery, radiation, and drug therapy. In general, drugs used to treat cancer are classified as chemotherapy. Because of the problems with current methods, there is a significant need for new therapies that are more effective and/or have reduced side effects.
Let us hear your thoughts below: